|
業務類別
|
Biotechnology |
|
業務概覽
|
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others. |
| 公司地址
| 201 Haskins Way, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 695-0677 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.lyell.com |
| 員工數量
| 300 |
| Dr. Lynn Seely,M.D. |
Interim Principal Financial Officer, Director, President and Chief Executive Officer |
美元 675.96K |
03/11/2025 |
| Ms. Veronica Sanchez Bulis |
Vice President, Corporate Controller and Principal Accounting Officer |
-- |
03/11/2025 |
| Mr. Stephen Hill |
Chief Operating Officer |
美元 516.74K |
21/04/2025 |
| Dr. Gary Lee, PhD |
Chief Scientific Officer |
-- |
21/04/2025 |
|
|
| Ms. Catherine J. Friedman |
Lead Independent Director |
21/04/2025 |
| Dr. Otis W. Brawley,M.D. |
Independent Director |
21/04/2025 |
| Dr. Lynn Seely,M.D. |
Interim Principal Financial Officer, Director, President and Chief Executive Officer |
03/11/2025 |
| Mr. William J. Rieflin |
Independent Director |
21/04/2025 |
| Mr. Mark Bachleda |
Director |
09/06/2025 |
| Dr. Richard D. Klausner, M.D. |
Chairman of the Board |
21/04/2025 |
| Dr. Elizabeth G. Nabel, M.D. |
Independent Director |
21/04/2025 |
| Dr. Sumant Ramachandra,M.D.,PhD |
Independent Director |
21/04/2025 |
|
|
|
|
